Showing 1 - 9 results of 9 for search 'Harrison, CN', query time: 0.02s
Refine Results
-
1
-
2
The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib by O'Sullivan, JM, Hamblin, A, Yap, C, Fox, S, Boucher, R, Panchal A, Alimam, S, Dreau, H, Howard, K, Ware, P, Cross, NCP, McMullin, MF, Harrison, CN, Mead, AJ
Published 2019Journal article -
3
Continuous Indexing of Fibrosis (CIF): improving the assessment and classification of MPN patients by Harrington, H, Ryou, H, Sirinukunwattana, K, Aberdeen, A, Grindstaff, G, Stolz, BJ, Byrne, H, Sousos, N, Godfrey, AL, Harrison, CN, Psaila, B, Mead, AJ, Rees, G, Turner, GDH, Rittscher, J, Royston, D
Published 2022Journal article -
4
Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies by Mesa, RA, Hudgens, S, Floden, L, Harrison, CN, Palmer, J, Gupta, V, McLornan, DP, McMullin, MF, Kiladjian, J-J, Foltz, L, Platzbecker, U, Fox, ML, Mead, AJ, Ross, DM, Oh, ST, Perkins, A, Leahy, MF, Deheshi, S, Donahue, R, Klencke, BJ, Verstovsek, S
Published 2023Journal article -
5
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms by Grockowiak, E, Korn, C, Rak, J, Lysenko, V, Hallou, A, Panvini, FM, Williams, M, Fielding, C, Fang, Z, Khatib-Massalha, E, García-García, A, Li, J, Khorshed, RA, González-Antón, S, Baxter, EJ, Kusumbe, A, Wilkins, BS, Green, A, Simons, BD, Harrison, CN, Green, AR, Lo Celso, C, Theocharides, APA, Méndez-Ferrer, S
Published 2023Journal article -
6
Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis by Gerds, AT, Savona, MR, Scott, BL, Talpaz, M, Egyed, M, Harrison, CN, Yacoub, A, Vannucchi, A, Mead, AJ, Kiladjian, J-J, O'Sullivan, J, García-Gutiérrez, V, Bose, P, Rampal, RK, Miller, CB, Palmer, J, Oh, ST, Buckley, SA, Mould, DR, Ito, K, Tyavanagimatt, S, Smith, JA, Roman-Torres, K, Devineni, S, Craig, AR, Mascarenhas, JO
Published 2020Journal article -
7
Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial by Harrison, CN, Nangalia, J, Boucher, R, Jackson, A, Yap, C, O'Sullivan, J, Fox, S, Ailts, I, Dueck, AC, Geyer, HL, Mesa, RA, Dunn, WG, Nadezhdin, E, Curto-Garcia, N, Green, A, Wilkins, B, Coppell, J, Laurie, J, Garg, M, Ewing, J, Knapper, S, Crowe, J, Chen, F, Koutsavlis, I, Godfrey, A, Arami, S, Drummond, M, Byrne, J, Clark, F, Mead-Harvey, C, Baxter, EJ, McMullin, MF, Mead, AJ
Published 2023Journal article -
8
Tamoxifen for the treatment of myeloproliferative neoplasms: a phase II clinical trial and exploratory analysis by Fang, Z, Corbizi Fattori, G, McKerrell, T, Boucher, RH, Jackson, A, Fletcher, RS, Forte, D, Martin, J-E, Fox, S, Roberts, J, Glover, R, Harris, E, Bridges, HR, Grassi, L, Rodriguez-Meira, A, Mead, AJ, Knapper, S, Ewing, J, Butt, NM, Jain, M, Francis, S, Clark, FJ, Coppell, J, McMullin, MF, Wadelin, F, Narayanan, S, Milojkovic, D, Drummond, MW, Sekhar, M, ElDaly, H, Hirst, J, Paramor, M, Baxter, EJ, Godfrey, AL, Harrison, CN, Méndez-Ferrer, S
Published 2023Journal article -
9
CNL and aCML should be considered as single entity based on molecular profiles and outcomes by Carreño-Tarragona, G, Alvarez-Larran, A, Harrison, CN, Martínez-Ávila, JC, Hernandez-Boluda, JC, Ferrer-Marin, F, Radia, DH, Mora Casterá, E, Francis, S, González-Martínez, T, Goddard, K, Perez-Encinas, M, Narayanan, S, Raya, JM, Singh, V, Toth, P, Gutiérrez, X, Amat Martinez, P, McIlwaine, L, Alobaidi, M, Mayani, K, McGregor, A, Stuckey, R, Psaila, B, Segura, A, Alvares, CL, Davidson, K, Osorio, S, Cutting, R, Sweeney, CP, Rufian, L, Moreno, L, Cuenca, I, Smith, J, Morales, ML, Gil-Manso, R, Koutsavlis, I, Wang, L, Mead, AJ, Rozman, M, Martínez-López, J, Ayala, R, Cross, NC
Published 2022Journal article